| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $79.0M | +21.8% |
| SG&A Expense | $15.3M | +57.7% |
| Operating Income | -$94.3M | -26.4% |
| Net Income | -$80.5M | -16.1% |
| EPS (Basic) | -$2.56 | +92.1% |
| EPS (Diluted) | -$2.56 | +92.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $74.3M | -50.6% |
| Short-term Investments | $144.6M | — |
| Current Assets | $227.0M | +41.9% |
| Total Assets | $274.9M | +68.6% |
| Current Liabilities | $17.3M | +48.6% |
| Total Liabilities | $17.3M | +46.5% |
| Stockholders' Equity | $257.7M | +268.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$70.2M | -25.7% |
| Investing Cash Flow | -$192.5M | — |
| Financing Cash Flow | $186.6M | +335.3% |